General publicity Sample Clauses
The General Publicity clause governs how parties may use each other's names, logos, or other identifying information in public communications or marketing materials. Typically, it sets out whether and how one party can announce the existence of the agreement, reference the other party as a client or partner, or issue press releases related to the relationship. This clause helps prevent unauthorized or potentially damaging disclosures, ensuring that both parties maintain control over their public image and sensitive business relationships.
General publicity. Any publicity regarding the subject matter of this CONTRACT must identify STATE as the sponsoring agency and must not be released without prior written approval from the STATE’s authorized representative. For purposes of this provision, publicity includes notices, informational pamphlets, press releases, research, reports, signs, websites, social media, and similar public notices prepared by or for the GRANTEE individually or jointly with others, or any subcontractors, with respect to the program, publications, or services provided resulting from this CONTRACT. All projects primarily funded by state grant appropriation must publicly credit the State of Minnesota, including on the GRANTEE’s website when practicable.
General publicity. The Parties acknowledge the importance of supporting each other's efforts to publicly disclose results and significant developments regarding the Compound and XenoPort Products and other activities in connection with this Agreement, beyond what is required by law, and each Party may make such disclosures from time to time with the approval of the other Party, which approval shall not be unreasonably withheld or delayed. Such disclosures may include, without limitation, achievement of Milestones under Section 6.2, significant events in the research, development and regulatory process with respect to the Compound or a Product, commercialization activities and the like. When a Party (the "Requesting Party") elects to make any such public disclosure under this Section 12.5, it will give the other Party (the "Cooperating Party") at least [**] notice to review and comment on such statement, it being understood that if the Cooperating Party does not notify the Requesting Party in writing within such [**] period of any reasonable objections, as contemplated in this Section 12.5, such disclosure shall be deemed approved; and in any event, the Cooperating Party shall work diligently and reasonably to agree on the text of any proposed disclosure in an expeditious manner. The principles to be observed in such disclosures shall be accuracy, compliance with applicable law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep investors informed regarding the Requesting Party's business. Accordingly, the Cooperating Party shall not withhold its approval of a proposed disclosure that complies with such principles.
General publicity. The Parties acknowledge the importance of supporting each other’s efforts to publicly disclose results and significant developments regarding Compounds and Products and other activities in connection with this Agreement, beyond what is required by applicable laws such as SEC disclosure rules and the like, and each Party may make such non-mandated disclosures from time to time [***]. When a Party (the “Requesting Party”) elects to make any such public disclosure under this Section 11.5, it will give the other Party (the “Cooperating Party”) [***] such statement, it being understood that if the Cooperating Party does not notify the Requesting Party in writing [***], as contemplated in this Section 11.5, such disclosure shall be deemed approved; and in any event, the Cooperating Party shall [***]. The principles to be observed in such disclosures shall be accuracy, compliance with applicable law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep investors informed regarding the Requesting Party’s business. Accordingly, the Cooperating Party shall not withhold its approval of a proposed disclosure that complies with such principles.
General publicity. Any publicity regarding the subject matter of this CONTRACT must identify STATE as the sponsoring agency and must not be released without prior written approval from the STATE’s authorized representative. For purposes of this provision, publicity includes notices, informational pamphlets, press releases, research, reports, signs, websites, social media, and similar public notices prepared by or for SCHOOL individually or jointly with others, or any subcontractors, with respect to the program, publications, or services provided resulting from this CONTRACT.
General publicity. Any publicity regarding the subject matter of this CONTRACT must identify STATE as the sponsoring agency and must not be released without prior written approval from the
General publicity. 10.1. The Provider must publicise the fact that the ESF and the party providing match funding, be it London Councils or an individual borough, are funding or part-funding your Project. This publicity should ensure that:
(a) participants are aware that their training is partly financed by the ESF and, as relevant, either London Councils or the individual borough providing match funding;
(b) the Provider raises awareness of the ESF and London Councils, or individual borough, ESF co-financing amongst potential participants and the general public;
(c) where it is impractical to use the logos of the ESF and London Councils, or as relevant the individual London local authority, in communications or publicity, wording must be included to the effect that the Project is part funded by the EU through the ESF and either London Councils or the relevant London local authority.
10.2. The Provider must publicise the project on their organisations website, undertaking such considerations as described in clause 10.1.